<DOC>
	<DOCNO>NCT00343629</DOCNO>
	<brief_summary>RATIONALE : Giving healthy volunteer sulindac capsule sulindac tablet may help doctor learn form drug may effective prevent cancer . PURPOSE : This randomized clinical trial study sulindac capsule see well work compare sulindac tablet healthy volunteer .</brief_summary>
	<brief_title>Sulindac Capsules Compared With Sulindac Tablets Healthy Volunteers</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare systemic exposure sulindac tablet vs sulindac capsule healthy volunteer . Secondary - Compare terminal half-life time peak drug concentration sulindac tablet vs sulindac capsule . OUTLINE : This randomize study . Participants randomize 1 2 treatment arm . - Arm I : Participants receive one sulindac capsule follow 7-10 day later one sulindac tablet . - Arm II : Participants receive one sulindac tablet follow 7-10 day later one sulindac capsule . Blood collect periodically treatment pharmacokinetic study . After completion study therapy , participant follow 7-10 day . PROJECTED ACCRUAL : A total 28 participant accrue study .</detailed_description>
	<mesh_term>Sulindac</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy volunteer PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Hemoglobin ≥ 12.0 g/dL ( woman ) Hemoglobin ≥ 13.5 g/dL ( men ) WBC &gt; 3,000/mm³ Platelet count &gt; 100,000/mm³ Absolute neutrophil count &gt; 1,500/mm³ Alkaline phosphatase ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN ALT ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 30 mL/min No history allergic reaction hypersensitivity sulindac NSAIDs , include aspirinsensitive asthma urticaria No condition interfere ingestion absorption oral medication No cancer within past 3 year except nonmelanomatous skin cancer , localize prostate cancer , carcinoma situ cervix , superficial bladder cancer previously treat &gt; 6 month ago No uncontrolled concurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Myocardial infarction past 6 month Chronic renal disease Chronic liver disease Hypertension difficult control Psychiatric illness social situation would limit study compliance No significant clinical disorder laboratory find would preclude study participation No consumption alcoholic caffeinated beverage ≥ 24 hour prior study drug administration blood sample draw Willing provide require biologic specimen PRIOR CONCURRENT THERAPY : More 6 month since prior investigational agent More 6 month since prior regular use ( defined frequency 7 consecutive day &gt; 3 week &gt; 21 day total ) concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase ( COX ) 2 inhibitor include , limited , follow : Ibuprofen Ketoprofen Naproxen More 6 week since prior oral corticosteroid More 30 day since prior concurrent use follow : Methotrexate Corticosteroids Warfarin Ticlopidine Clopidogrel Low molecular weight heparin Abciximab Dipyridamole Eptifibatide Tirofiban Lithium Cyclosporine Hydralazine Angiotensinconverting enzyme ( ACE ) inhibitor ACEreceptor antagonist allow Angiotensinreceptor blocker Ginkgo Ketorolac Levofloxacin Loop diuretic Meadowsweet Selective serotonin reuptake inhibitor Danaparoid No concurrent regular aspirin use unless prescribed physician prevention A maximum one aspirin ( 81 mg/day ) allow No concurrent herbal product ( e.g. , saw palmetto Hypericum perforatum [ St. John 's wort ] )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>